gp100 mRNA vaccine

The **gp100 mRNA vaccine** is an investigational cancer vaccine designed to encode the melanoma-associated antigen **gp100 (glycoprotein 100)**. This vaccine utilizes messenger RNA technology to direct host cells to produce the gp100 protein, which is then presented via antigen-presenting cells, stimulating a tumor-specific immune response. Its mechanism centers on activating both CD8+ cytotoxic T cells and CD4+ helper T cells against peptides derived from gp100 presented on MHC molecules, thereby targeting melanoma cells that express this antigen. The vaccine has primarily been explored in clinical trials for melanoma, often in combination with mRNA encoding other melanoma-associated antigens, and sometimes as part of dendritic cell-based vaccine approaches or formulated with immunostimulatory molecules like CD40L, CD70, and TLR4. Trials have included both "naked" mRNA (buffer formulation) and more advanced protamine or Lipoplex/LNP formulations. Clinical studies consistently demonstrate immunogenicity—meaning the induction of tumor-specific T cell responses—and some observed partial and complete clinical responses in melanoma patients, although overall survival and long-term benefit remain under investigation[1][4][3].

Other names

gp100 mRNA melanoma vaccinegp-100 mRNA melanoma vaccinegp 100 mRNA melanoma vaccine